Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
521
datasets available to search
ShareScore release 0.9.0
Dataset results
521 results for “Patient survival”
A Novel Parameter LIT/N That Predicts Survival in COVID-19 ICU Patients
ClinicalTrials.gov study NCT05520918. IPD Sharing: NO. Countries: 1. Publications: 4.
Predictive Value of FDG-TEP During Radiotherapy or Chemo-radiotherapy in Patients With NCSC on the One-year Survival
ClinicalTrials.gov study NCT01261598. IPD Sharing: NO. Countries: 1. Publications: 3.
Data from: Identification of biomarkers for Barcelona Clinic Liver Cancer staging and overall survival of patients with hepatocellular carcinoma
Open the record for dataset details and reuse information.
Data from: Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based on time-series data
Open the record for dataset details and reuse information.
Data from: Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients
Open the record for dataset details and reuse information.
Data from: Short-term and medium-term survival of critically ill patients with solid tumours admitted to the intensive care unit: a retrospective analysis
Open the record for dataset details and reuse information.
Metabolomics dataset for identification of metabolites associated with survival in lung cancer patients under treatment
<p>Non small cell lung cancer patients' serum samples were collected before treatment. The samples were analyzed by metabolomics using high resolution NMR and untargeted lipidomics using high resolution UPLC-MS. The data was used to identify the predictors of overall survival in the patients after they underwent treatment.</p>
Data from: Long‐term follow‐up, quality of life and survival of Lambert‐Eaton myasthenic syndrome patients
Objective To study survival and characterize long-term functional impairments as well as health-related quality of life (HRQOL) of Lambert-Eaton myasthenic syndrome (LEMS) patients. Methods In this observational study, survival of LEMS patients, separately for non-tumor (NT) and small-cell lung cancer (SCLC), was compared to the Dutch general population and to patients with SCLC. Disease course in LEMS patients was recorded retrospectively. Several scales for functional impairments and health-related quality of life were assessed. Results We included 150 LEMS patients. Survival was similar to the general population in 65 NT-LEMS patients. Tumor survival was significantly longer in 81 SCLC-LEMS patients compared to non-LEMS SCLC patients (overall median survival 17 vs. 7.0 months, p<0.0001). At diagnosis, 39 patients (62%) of 63 patients with complete follow-up data were independent for ADL activities, improving to 85% at 1-year follow-up. Physical HRQOL composite score (55.9) was significantly lower than in the general population (76.3, p<0.0001) and comparable to myasthenia gravis (60.5) Mental HRQOL composite score was 71.8 in LEMS patients, comparable to the general population (77.9, p=0.19) and myasthenia gravis (70.3). Conclusions This study shows NT-LEMS patients have normal survival. SCLC-LEMS patients have an improved tumor survival, even after correcting for tumor stage. A majority of LEMS patients report a stable disease course and remain or become independent for self-care after treatment.
Association between Dysregulated Expression of Ca2+ and ROS-Related Gene Pairs and Breast Cancer Patient Survival
<p>This file is composed by two documents:</p> <ul> <li>Supplementary Table 1 containing an Excel file with data on gene expression, differential gene expression (tumoral versus normal), and survival outcomes related to redox (sheet 1) and calcium-related (sheet 2) genes.</li> <li>Suplementary Table 2 including a table summarizing the primary functions of selected redox- and calcium-related genes and various studies reporting their impact on breast cancer</li> </ul> <p>Both supplementary tables belongs to the study <strong><strong>Association between Dysregulated Expression of Ca2+ and ROS-Related Gene Pairs and Breast Cancer Patient Survival</strong></strong>, published in <strong>Molecular Diagnosis and therapy </strong></p>
postoperative survival of patients with pancreatic ductal adenocarcinoma
<p>Postoperative information of pancreatic cancer patients</p>
ESMO-GROW checklist for the publication PD-1/PD-L1 blockade plus abnobaViscum® therapy is associated with improved survival in advanced or metastasized NSCLC patients, a real-world data registry study according to the ESMO-GROW criteria
Open the record for dataset details and reuse information.
Data from: Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial
Objective: To determine whether treatment with recombinant human thrombomodulin (rhTM) increases survival among severe septic patients with sepsis-induced disseminated intravascular coagulation (DIC) Design: Single-center, open-label, randomized controlled trial Setting: Single tertiary hospital Participant: 92 severe septic patients with sepsis-induced DIC Interventions: Patients with DIC scores ≥4, as defined by the Japanese Association of Acute Medicine, were diagnosed with DIC. Randomization was performed by the envelope method. The treatment group (rhTM group, n = 47) was intravenously treated with rhTM within 24 h of admission (day 0), and the control group (n = 45) did not receive any anti-coagulants, except in cases of deep venous thrombosis and pulmonary embolism. Primary and secondary measurements: Data were collected on days 0 (admission), 1, 2, 3, 5, 7, and 10. The primary outcome was survival at 28 and 90 days. The secondary endpoints comprised changes in DIC scores, platelet counts, D-dimer, antithrombin III (ATIII), and C-reactive protein (CRP) levels, and Sequential Organ Failure Assessment (SOFA) scores. All analyses were conducted on an intent-to-treat basis. Main Results: The 28-day survival rates were 84 and 83% in the control and rhTM groups, respectively (p = 0.745, log rank test). The 90-day survival rates were 73% and 72% in the control and rhTM groups, respectively (p = 0.94, log rank test). Meanwhile, the rates of recovery from DIC (<4) were significantly higher in the rhTM group than in the control group (p = 0.001, log rank test). Relative change from baseline of D-dimer levels were significantly lower in the rhTM group than in the control group, on day 3 and 5. Conclusion: rhTM treatment decreased D-dimer levels and facilitated DIC recovery in severe septic patients with sepsis-induced DIC. However, the treatment did not improve survival in this cohort.
Dynamics of glucose metabolism after liver transplantation: Prediabetes as a window of opportunity for patient survival and long‐term kidney function
<p>Posttransplantation diabetes mellitus (PTDM) is a relevant complication following liver transplantation with profound impact on morbidity and mortality. To date, little is known about the evolution and dynamics of glucose metabolism and the impact of prediabetes in long-term follow-up. To address this issue, all consecutive adult liver transplant recipients (n=429) from a European university hospital transplant center between 2007 and 2017 were analyzed retrospectively. In patients without pre-existing diabetes (n=327), we conducted a longitudinal characterization of glucose metabolism. Median follow-up was 37 [9-64, IQR] months. Median prevalence of prediabetes was 39 [37-39]% and of PTDM 21 [17-22]%. Throughout follow-up, intra-individual glucose regulation of patients was highly variable, continuously fluctuating between different states of glucose metabolism (normal glucose tolerance, prediabetes, PTDM). Whereas overall survival and long-term kidney function of patients with PTDM were significantly lower than that of patients with normal glucose metabolism, prediabetes was not associated with adverse outcome. This study provides new insight into the dynamics and impact of glucose metabolism after liver transplantation. Unlike PTDM, prediabetes is not associated with adverse outcome, providing a window of opportunity for targeted intervention. The results underline the need for constant screening and intervention in post-transplant care of liver allograft recipients.</p>
Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy
ClinicalTrials.gov study NCT07290764. IPD Sharing: NO. Countries: 1. Publications: 0.
Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France
ClinicalTrials.gov study NCT04282421. IPD Sharing: NO. Countries: 0. Publications: 2.
Prognostic Determinants of Survival and Quality of Life in Prevalent End-stage Kidney Disease Patients
ClinicalTrials.gov study NCT03910426. IPD Sharing: NO. Countries: 0. Publications: 1.
Survival of Double Inlet Left Ventricle Patients Without Fontan Circulation
ClinicalTrials.gov study NCT03667144. IPD Sharing: NO. Countries: 0. Publications: 8.
A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment
ClinicalTrials.gov study NCT01990261. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Long-term Survival and Renal Outcomes in Critically Ill Patients After Acute Kidney Injury: Swedish Multi-centre Cohort Study
ClinicalTrials.gov study NCT02424747. IPD Sharing: Not stated. Countries: 0. Publications: 8.
Is TIme From adMission to surgEry an Independent Prognostic Factor for Survival of Patients With Gastro-intestinal Perforation Associated With Septic Shock: (TIME) An Italian Intersocietary Retrospect
ClinicalTrials.gov study NCT04811755. IPD Sharing: NO. Countries: 0. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.